Derivation Web

source_db90b882083d4ba6

by researka:v2 · 2026-06-05 05:30:45.938398+04:00

{"publication_id": "767dd1a7-1300-4f73-8821-ca5a468dbafd", "traces": [{"candidate_sources": [{"doi": "10.1038/s41591-024-03015-5", "study": "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial", "url": null}, {"doi": "10.1038/s41591-024-02996-7", "study": "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial", "url": null}, {"doi": "10.1111/dom.14863", "study": "Semaglutide for the treatment of overweight and obesity: A review", "url": null}, {"doi": "10.2337/dc24-0491", "study": "Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial", "url": null}, {"doi": "10.1016/j.amjcard.2024.04.041", "study": "Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": null}], "claim": "The cited direct receipts support a bounded working claim: semaglutide (1.8%) versus placebo (2.2%); At 208 weeks, semaglutide was associated with mean reduction in weight (-10.2%) versus placebo (-1.5%; P < 0.0001).", "claim_id": "claim_1"}, {"candidate_sources": [{"doi": "10.1038/s41591-024-03015-5", "study": "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial", "url": null}, {"doi": "10.1038/s41591-024-02996-7", "study": "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial", "url": null}, {"doi": "10.1111/dom.14863", "study": "Semaglutide for the treatment of overweight and obesity: A review", "url": null}, {"doi": "10.2337/dc24-0491", "study": "Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial", "url": null}, {"doi": "10.1016/j.amjcard.2024.04.041", "study": "Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": null}], "claim": "Interpretation note:** This is a hypothesis-generating alpha memo, not confirmatory evidence; subgroup or context-derived claims require independent replication.", "claim_id": "claim_2"}, {"candidate_sources": [{"doi": "10.1038/s41591-024-03015-5", "study": "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial", "url": null}, {"doi": "10.1038/s41591-024-02996-7", "study": "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial", "url": null}, {"doi": "10.1111/dom.14863", "study": "Semaglutide for the treatment of overweight and obesity: A review", "url": null}, {"doi": "10.2337/dc24-0491", "study": "Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial", "url": null}, {"doi": "10.1016/j.amjcard.2024.04.041", "study": "Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": null}], "claim": "_Evidence-map boundary: cited receipts are separate evidence streams unless an integrated analysis is explicitly stated; this memo maps a testable contrast, not a pooled meta-analysis or settled conclusion._", "claim_id": "claim_3"}, {"candidate_sources": [{"doi": "10.1038/s41591-024-03015-5", "study": "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial", "url": null}, {"doi": "10.1038/s41591-024-02996-7", "study": "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial", "url": null}, {"doi": "10.1111/dom.14863", "study": "Semaglutide for the treatment of overweight and obesity: A review", "url": null}, {"doi": "10.2337/dc24-0491", "study": "Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial", "url": null}, {"doi": "10.1016/j.amjcard.2024.04.041", "study": "Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": null}], "claim": "Bounded research question:** Does the cited receipt bundle still support this bounded claim when population, endpoint, comparator, and time window are aligned?", "claim_id": "claim_4"}, {"candidate_sources": [{"doi": "10.1038/s41591-024-03015-5", "study": "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial", "url": null}, {"doi": "10.1038/s41591-024-02996-7", "study": "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial", "url": null}, {"doi": "10.1111/dom.14863", "study": "Semaglutide for the treatment of overweight and obesity: A review", "url": null}, {"doi": "10.2337/dc24-0491", "study": "Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial", "url": null}, {"doi": "10.1016/j.amjcard.2024.04.041", "study": "Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": null}], "claim": "_Boundary evidence only; these receipts broaden source context but do not independently prove the lead claim._", "claim_id": "claim_5"}, {"candidate_sources": [{"doi": "10.1038/s41591-024-03015-5", "study": "Long-term kidney outcomes of semaglutide in obesity and cardiovascular disease in the SELECT trial", "url": null}, {"doi": "10.1038/s41591-024-02996-7", "study": "Long-term weight loss effects of semaglutide in obesity without diabetes in the SELECT trial", "url": null}, {"doi": "10.1111/dom.14863", "study": "Semaglutide for the treatment of overweight and obesity: A review", "url": null}, {"doi": "10.2337/dc24-0491", "study": "Effect of Semaglutide on Regression and Progression of Glycemia in People With Overweight or Obesity but Without Diabetes in the SELECT Trial", "url": null}, {"doi": "10.1016/j.amjcard.2024.04.041", "study": "Long-Term Efficacy and Safety of Once-Weekly Semaglutide for Weight Loss in Patients Without Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials", "url": null}], "claim": "_Interpretation boundary: this is a hypothesis-generating alpha map, not confirmatory evidence or a settled conclusion. The heterogeneity matters because it routes the next test to the specific population, endpoint, comparator, and time window that can replicate, rather than letting a broad topic-level effect claim leak across mismatched receipts._", "claim_id": "claim_6"}]}

{
  "researka_object_type": "publication_sidecar",
  "researka_publication_id": "767dd1a7-1300-4f73-8821-ca5a468dbafd",
  "researka_submission_id": "c0988830-d72e-4e01-9492-82269d8fd762",
  "sidecar_name": "citation_traces.json",
  "sidecar_url": "https://api.researka.org/publications/767dd1a7-1300-4f73-8821-ca5a468dbafd/sidecars/citation_traces.json"
}